Days After US Aflibercept Approval, Sandoz Is Hit By Regeneron Lawsuit

Originator Alleges BPCIA Patent Dance Failings Over Filing For Proposed Eylea Biosimilar

 
• By Dave Wallace
  
Eye with reflection of word "legal"
Regeneron says Sandoz has not followed the BPCIA’s “patent dance” • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin